Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2020

01.03.2020 | editorial

CAR(-T)s are on the road

verfasst von: Dr. Jakob D. Rudzki

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

CAR-T cell therapies (chimeric antigen receptor-T cell therapies) are increasingly becoming part of clinical practice since the approval of two compounds tisagenlecleucel (Kymriah ®—Novartis, Morris Plains, NJ, USA) and axicabtagene ciloleucel (Yescarta ®—Gilead/kite, Santa Monica, CA, USA) in 2017 in the US market and a bit later in 2018 in Europe and other parts of the world, as well. Starting with r/r pALL (relapsed/refractory B-cell precursor acute lymphoblastic leukemia) up to the age of 25 years and young adults (Kymriah) and continuing with r/r DLBCL (diffuse large B cell lymphoma) (Kymriah and Yescarta), these two indications are currently the main focus of commercial CAR-T cell therapy. However, new compounds for mentioned indications and new compounds for new indications like for multiple myeloma are attracting more and more attention. …
Literatur
Metadaten
Titel
CAR(-T)s are on the road
verfasst von
Dr. Jakob D. Rudzki
Publikationsdatum
01.03.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00576-2